Chengdu Yilexin Biotechnology

Chengdu Yilexin Biotechnology Co., Ltd., operating as Illumaxbio, is a national high-tech enterprise founded on August 30, 2018. The company specializes in the research and manufacturing of advanced diagnostic systems, including single-test chemiluminescence immunoassay (CLIA) systems, multiplex immunoassay systems, and laboratory automation products. Illumaxbio provides comprehensive solutions and establishes an open contract development and manufacturing (CDMO) platform for its immunoassay technologies.

The founder and CEO, Xingpeng Zhang, holds a BMEE from Xi'an Jiao Tong University and an MBA from the University of Electronic Science and Technology of China, with two decades of experience in the in-vitro diagnostic (IVD) industry. The core team began their IVD research careers in 2006. Key milestones for the company include the development of a fully point-of-care (POCT) CLIA system in 2019, the opening of its Wenjiang production base in Chengdu in 2020, and receiving NMPA approval for its Lumiflx 16 and Lumilite 8 systems in 2021. By 2022, it had obtained over 60 CE certifications for its single-dose chemiluminescence reagents.

The company's business model focuses on providing what it terms "5A-level" diagnostic systems: Anytime, Anyplace, Anyone, Affordable, and Accuracy. Its product portfolio includes analyzers like the Lumilite 8 and Lumiflx 16, alongside a wide array of diagnostic reagents for markers related to cardiac conditions, inflammation, and more. Illumaxbio serves a global market, with products distributed across Europe, the Middle East, South Asia, South America, Africa, and China. Revenue is generated through the sale of these diagnostic instruments and reagents, as well as providing OEM and CDMO services to partners.

Keywords: chemiluminescence immunoassay, point-of-care testing, in-vitro diagnostics, multiplex immunoassay, laboratory automation, diagnostic reagents, CLIA system, medical devices, POCT, immunoassay analyzer, CDMO, single-test system, Lumilite 8, Lumiflx 16, Xingpeng Zhang, diagnostic solutions, CE certification, NMPA approved, cardiac markers, inflammation markers